Governance Marker Therapeutics, Inc.

MRKR

US57055L2060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
1.330 ^USD	-1.48%		-3.62%	-10.74%

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Executive Committee: Marker Therapeutics, Inc.

Manager

Positions heldSince

Juan Vera

46 year

Comptroller/Controller/Auditor	16/11/2023
Chief Executive Officer	30/04/2023
Director of Finance/CFO	16/11/2023
President	30/04/2023
Corporate Secretary	-

Elizabeth Donnelly

Chief Administrative Officer

31/08/2015

Kenneth Ray Moseley

69 year

General Counsel

22/10/2018

Gerald Garrett

61 year

Chief Tech/Sci/R&D Officer

31/10/2019

Edmund Cheung

Human Resources Officer

31/12/2020

Monic Stuart

Chief Tech/Sci/R&D Officer

07/05/2023

F. Andrew Dorr

Chief Tech/Sci/R&D Officer

Mary Newman

67 year

General Counsel

Composition of the Board of Directors: Marker Therapeutics, Inc.

Director

CommitteesSince

Norman Eansor

65 year

Governance Committee	23/05/2022
Nominating Committee	23/05/2022
Audit Committee Chair	23/05/2022
Compensation Committee Chair	23/05/2022

Katharine Knobil

62 year

Audit Committee	07/12/2021
Compensation Committee	25/08/2024
Governance Committee Chair	07/12/2021
Nominating Committee Chair
Governance Committee	13/09/2022
Nominating Committee	13/09/2022

Steven Elms

62 year

Governance Committee	05/08/2019
Nominating Committee	05/08/2019
Audit Committee	05/08/2019
Compensation Committee	18/05/2020

Kathryn Corzo

65 year

Director/Board Member

31/10/2025

Juan Vera

46 year

Director/Board Member

16/10/2018

Latest Appointments: Marker Therapeutics, Inc.

11-05	Marker Therapeutics, Inc. Appoints Kathryn Penkus Corzo to Board of Directors, Effective November 1, 2025	CI
11-05	Marker Therapeutics appoints Kathryn Penkus Corzo to board of directors	RE
30/01/25	Marker Therapeutics, Inc. Announces Resignation of John Wilson from the Board of Directors	CI
08/05/23	Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer	CI
28/04/23	Marker Therapeutics, Inc. Announces Management Changes	CI
28/04/23	Marker Therapeutics, Inc. Announces Chief Executive Officer Changes	CI
16/03/23	Marker Therapeutics, Inc. Announces Mythili Koneru, to Resign as Chief Medical Officer, Effective as of April 9, 2023	CI

More news

Former Officers and Directors: Marker Therapeutics, Inc.

Insider

Positions held

SinceUntil

John Wilson

Director/Board Member	16/10/2018	23/01/2025
Chief Executive Officer	-	-
Independent Dir/Board Member	16/10/2018	23/01/2025

Tsvetelina Hoang

Chief Tech/Sci/R&D Officer

22/10/2018

31/07/2024

Nadia Agopyan

General Counsel

14/08/2019

29/02/2024

Eliot Lurier

Comptroller/Controller/Auditor	-	16/11/2023
Director of Finance/CFO	29/06/2023	16/11/2023

Michael Loiacono

Comptroller/Controller/Auditor	24/08/2016	29/06/2023
Director of Finance/CFO	24/08/2016	26/11/2018
Corporate Secretary	24/08/2016	29/06/2023
Treasurer	24/08/2016	29/06/2023

David Laskow-Pooley

Director/Board Member	18/03/2015	05/06/2023
Independent Dir/Board Member	18/03/2015	05/06/2023

Peter Hoang

Director/Board Member	24/09/2017	30/04/2023
Chief Executive Officer	24/09/2017	30/04/2023
President	24/09/2017	30/04/2023

Mythili Koneru

Chief Tech/Sci/R&D Officer	30/11/2019	08/04/2023
Corporate Officer/Principal	06/02/2019	30/11/2019

Neda Safarzadeh

Investor Relations Contact	31/12/2021	30/11/2022
Public Communications Contact	31/12/2021	30/11/2022
Sales & Marketing	31/12/2021	30/11/2022

Anthony H. Kim

Director of Finance/CFO

26/11/2018

29/09/2022

Frederick Wasserman

Director/Board Member	31/12/2015	16/10/2018
Chairman	16/10/2018	23/05/2022
Independent Dir/Board Member	31/12/2015	23/05/2022

Ann Leen

Chief Tech/Sci/R&D Officer	22/10/2018	31/01/2020
Founder	22/10/2018	31/01/2020

Glynn Wilson

Comptroller/Controller/Auditor	06/02/2005	-
Director/Board Member	06/02/2005	26/08/2009
Chief Executive Officer	09/09/2010	24/09/2017
Chairman	26/08/2009	16/10/2018
Director of Finance/CFO	06/02/2005	24/08/2016
Public Communications Contact	06/02/2005	24/09/2017
President	26/04/2017	24/09/2017
Corporate Secretary	06/02/2005	-

Mark Reddish

Director/Board Member	21/11/2011	16/10/2018
Independent Dir/Board Member	21/11/2011	16/10/2018
Corporate Officer/Principal	21/11/2011	-

Sherry Grisewood

Director/Board Member	19/03/2013	16/10/2018
Independent Dir/Board Member	19/03/2013	16/10/2018

Joshua Silverman

Director/Board Member	31/07/2016	30/09/2018
Independent Dir/Board Member	31/07/2016	30/09/2018

Richard Kenney

Chief Tech/Sci/R&D Officer

05/12/2017

John Bonfiglio

Director/Board Member	22/07/2015	26/04/2017
Chief Operating Officer	17/07/2016	26/04/2017
President	17/07/2016	26/04/2017

Patrick Yeramian

Chief Tech/Sci/R&D Officer

31/01/2015

31/12/2016

Ali Behbahani

Director/Board Member

31/12/2016

James Fuller

Director/Board Member

17/05/2012

05/02/2013

Lynn M. DePippo

Director/Board Member

08/09/2010

22/08/2012

Denis Corin

Director/Board Member	08/11/2010	07/05/2012
Chief Executive Officer	31/10/2006	26/08/2009
Director of Finance/CFO	20/07/2010	07/05/2012
President	31/10/2006	07/05/2012

Robert Z. Florkiewicz

Chief Tech/Sci/R&D Officer

10/04/2012

Tracy Moore

Director of Finance/CFO

26/08/2009

15/07/2010

Patrick A. McGowan

Director/Board Member	04/12/2005	30/06/2009
Director of Finance/CFO	04/12/2005	-
Corporate Secretary	04/12/2005	-
Treasurer	04/12/2005	-

Alan P. Lindsay

Chairman

31/12/2006

30/06/2009

Terry Pearson

Director/Board Member

04/12/2005

Karl Erik Hellström

Director/Board Member

04/12/2005

Edward Farrauto

Director of Finance/CFO

30/04/2004

07/10/2005

Konstantine Sarafis

President

25/09/2005

Ronald Handford

President

06/02/2005

Timothy Z. Vitalis

Director/Board Member

29/02/2000

Venissa Izaguirre

Corporate Officer/Principal

Thad Morris

Investor Relations Contact	-	-
Public Communications Contact	-	-

Larry Morningstar

Public Communications Contact

10/12/2009

Aris Morfopoulos

Chief Executive Officer	-	-
President	-	-

Norman MacKinnon

Director/Board Member

James Dale Davidson

Director of Finance/CFO	-	-
Corporate Secretary	-	-

Grant R. Atkins

Director of Finance/CFO

Shelia Sterr

Human Resources Officer

Wilfred Jefferies

Chairman	-	30/08/2009
Chief Tech/Sci/R&D Officer	-	-

Age distribution of managers

Parity Men Women

Male	9
Female	3

Of which Executive Committee

Male	6
Female	2

Of which Directors

Male	4
Female	1

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Employees

Sector

Biotechnology & Medical Research

More about the company